VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

VistaGen Therapeutics reports Q1 loss, focuses on FDA approval

VistaGen Therapeutics faces financial challenges with increased expenses but shows strength in its innovative drug candidates targeting mental health disorders. The company's opportunities lie in FDA approval for fasedienol and market expansion for its pherine drug candidates.

VistaGen reports positive trial results and financial stability in Q2

VistaGen Therapeutics showcased positive trial results and financial stability, emphasizing the potential of their pherine pipeline to create value and improve lives.
While facing challenges such as increased expenses and operational concerns, the company's commitment to advancing treatments presents opportunities for growth and market expansion.
Analyst interest in study details and timelines reflects investor confidence in VistaGen's research programs and potential market impact.
Overall, VistaGen's Q2 performance highlights progress in lead programs and a solid financial foundation for future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended September 30, 2023. “Vistagen achieved multiple important milestones in recent months, significantly advancing our innovative.

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that company management will present and host one-on-one meetings at the Stifel 2023 Healthcare Conference taking place November 14 – 15, 2023 at the Lotte New York Palace Hotel in New York City. Stifel 2023 Healthcare Co.

Vistagen to Present at Stifel 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the Company will present at two upcoming scientific conferences in November. “Vistagen's presentations highlight the significant progress we have made to advance new therapies to address urgent unmet patient needs,” said.

Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, November 9, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to provide a corporate update and report results for its fiscal year 2024 second quarter ended S.

Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the Company will present and host one-on-one meetings at the Jefferies Biotech CNS/Neuro Summit taking place October 11 – 12, 2023 in New York City, New York. Jefferies Inaugural Biotech CNS/Neuro Summit Details Fire.

Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase common stock (or pre-funded warrants in.

Vistagen Announces Pricing of $100 Million Underwritten Offering

Black Rifle Coffee

Celcuity

CompoSecure

RumbleON

Sientra

Wheels Up Experience

The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.

The 7 Best Short-Squeeze Stocks to Buy Now: September 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the Company's five investigational neuroactive nasal sprays, demonstrated statistically significant improvement versus placebo in an exploratory Phase 2A study for acute management of the symptoms of pre.

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)---- $VTGN #menopause--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Fuji Pharma Co., Ltd. (“Fuji”) (TSE: 4554), a pharmaceutical company specializing in development, manufacture and marketing in the fields of women's healthcare and acute medical care, today announced they have entered into a time-.

Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen's Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. “We are delighted to welc.

Vistagen Appoints Cindy Anderson as Chief Financial Officer

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Mark Flather - VP of IR Shawn Singh - CEO Josh Prince - SVP of Business Operations Conference Call Participants Andrew Tsai - Jefferies Joanne Lee - Maxim Group Operator Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 First Quarter Corporate Update Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded, Thursday, August 10, 2023.

Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 first quarter ended June 30, 2023. "The positive outcome of our PALISADE-2 study demonstrated that fasedienol significantly reduced the mean Subjec.

Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results

Vistagen Therapeutics Inc (NASDAQ:VTGN) is continuing its recent volatility, after today's news that healthcare investment name Commodore Capital Master LP has become a top shareholder with a 19.7% stake.

Outperforming Biotech Pops on Shareholder Buzz

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update and report results for its fiscal year 2024 first quarter ended June.

Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023

Vistagen Therapeutics (NASDAQ: VTGN ) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into penny stock status and coming dangerously close to the $1 per share mark.

Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?

SAGE Therapeutics

Sage Therapeutics Inc (NASDAQ:SAGE) is crumbling to record lows today, down 52.2% at $17.25 at last check, earlier hitting a low of $16.69.

2 Biotech Stocks Staging Large Swings

Are you looking for penny stocks to buy? Are you grappling with the push and pull of skeptics saying penny stocks aren't worth it or penny stocks are a scam?

VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here's Why

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol (PH94B) nasal spray in adults diagnosed with social anxiety disorder (SAD). The trial met its primary e.

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats. The study demonstrated that a single intranasal administration of radiolabeled itruvone ([14C]PH10) was essentially undetectable.

Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray's Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the Canadian Intellectual Property Office (CIPO) issued a Notice of Allowance for a patent related to the use of AV-101 for reduction of dyskinesia (sudden uncontrolled movements) induced by the administration of lev.

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson's Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results.

Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Wednesday, June 28, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to report results for its fiscal year 2023 ended March 31, 2023 and provide a corporate update. Event: Vi.

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that, on June 22, 2023, Vistagen received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (Nasdaq) indicating that Vistagen has regained full compliance with the minimum $1.00 bid price per s.

Vistagen Regains Full Compliance with Nasdaq Listing Requirements

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced favorable safety and tolerability data from its U.S. Phase 1 clinical trial of itruvone (PH10), the Company's investigational rapid-onset pherine nasal spray for the treatment of major depressive disorder (MDD). Results fro.

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

Bone Biologics Corp

Fresh2 Group Ltd

Yield10 Bioscience

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

News for VistaGen Therapeutics Stock (VTGN)